Clinical trials: Hematology
MDS, Immunodeficiency
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
Background: Stem cells are immature blood cells that grow in the bone marrow and produce all of the cells needed for normal blood and immunity.
- Conditions
- MDS, Immunodeficiency, GATA2
- Trial name
- NCT00923364
- Testing
- Cyclophosphamide (CTX, Cytoxan), Fludarabine(Fludara,Berlex Laboratories), Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT03246906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Factor XIII Deficiency
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Congenital deficiency of factor XIII is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII.
- Trial name
- NCT00945906
- Testing
- FXIII Concentrate (Human) (FXIII)
- Where
- 25 sites in United States
- Volunteers
- 61 people
- Sponsor
- CSL Behring
Thalassemia
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Thalassemia is an inherited blood disorder that can result in mild to severe anemia. Regular blood transfusions, which refresh the healthy red blood cell supply, are one treatment for thalassemia.
- Trial name
- NCT00872833
- Where
- 9 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Carelon Research
Multiple Myeloma
Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation
The purpose of this study is to improve the efficacy of the HDC regimen by adding a novel, "targeted" means administering a variation of total body irradiation (TBI) radiation i.e., total skeletal irradiation (TSI) administered…
- Trial name
- NCT01182233
- Testing
- Total Skeletal Irradiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Rochester
Pain, Sickle Cell Disease
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain…
- Trial name
- PRESENCE (NCT06374238)
- Testing
- CBT+ Health coach, CBT w/o Health Coach ( self-guided), Usual Care
- Where
- 14 sites in United States
- Volunteers
- 390 people
- Sponsor
- University of Pittsburgh
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
The standard approach to managing chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) is to wait until you have symptoms before treatment is given.
- Conditions
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT03207555
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Thrombotic Microangiopathy
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA.
- Trial name
- NCT04557735
- Testing
- Ravulizumab, Best Supportive Care
- Where
- 26 sites in United States, Israel and 5 more
- Volunteers
- 41 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acute Myeloid Leukemia, First Line Therapy
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid…
- Trial name
- NCT06928376
- Testing
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7"
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chinese PLA General Hospital
Disease of the Blood
Collection of Peripheral Blood Mononuclear Cells From Healthy Subjects
In accordance with the selection criteria, component blood collection will be carried out and peripheral blood mononuclear cells will be isolated, cryopreserved and in vitro culture of peripheral blood mononuclear cells.
- Trial name
- NCT05560217
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
This phase I trial is studying the side effects and best dose of sorafenib in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00131989
- Testing
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
This research is a phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention to learn whether it works in treating a specific cancer.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01643668
- Testing
- Busulfan, Clofarabine, Allogeneic Stem Cell Infusion
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Thrombocytopenia Associated With Chronic Liver Disease
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
The main aim of this clinical trial is to assess the safety and efficacy of a single dose of PN20 in treatment of thrombocytopenia in adult patients with chronic liver disease undergoing an elective procedure.
- Trial name
- NCT07446491
- Testing
- PN20
- Where
- 8 sites in China
- Volunteers
- 54 people
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Skin Health, Skin Aging of Face and Hands
The Effect of Nutritional Supplementation on Actinic Purpura: A Pilot Study
Purpura is a macule or papule of blood in the skin. It is mostly seen in mature skin that is often prone to significant bruising.
- Conditions
- Skin Health, Skin Aging of Face and Hands, Healthy, Ecchymosis
- Trial name
- NCT06840574
- Testing
- Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, Low Dose Vitamin C, High Dose Vitamin C
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Standard Process Inc.
Multiple Myeloma
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomid-refractory RRMM who have…
- Trial name
- FUMANBA-03 (NCT06464991)
- Testing
- Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomide
- Where
- 28 sites in China
- Volunteers
- 240 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Pediatric ALL, B Cell, Minimal Residual Disease
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease.
- Trial name
- NCT04604691
- Testing
- Blinatumomab for Injection
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Iron-deficiency
Imaging Intravenous Iron
The aim of this study is to track where the iron goes in different tissues in the hours, days and weeks after an intravenous iron infusion.
- Trial name
- NCT05609318
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Multiple Myeloma
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.
Multiple myeloma (MM) is the second most common hematological disease in Denmark with an incidence of approximately 350 diagnosed cases per year.
- Trial name
- NCT05306587
- Testing
- Darzalex
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Thomas Lund
Sickle Cell Disease, Hematological Diseases
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participants with severe sickle cell disease (SCD).
- Conditions
- Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
- Trial name
- NCT03745287
- Testing
- Exa-cel
- Where
- 17 sites in United States, Belgium and 5 more
- Volunteers
- 63 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Kidney Failure, Chronic, Multiple Myeloma
Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure
The purpose of this study is to determine whether a combined bone marrow and kidney transplant will be effective in treating stage II or greater multiple myeloma and associated kidney failure.
- Trial name
- NCT00062621
- Testing
- Combined bone marrow and kidney transplant
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.